CureVac stock price, funding rounds, valuation and financials

CureVac has raised $1.11 b in total funding. CureVac valuation is $1.5 b, and annual revenue was €12.55 m in FY 2018

$1.5 B

CureVac Mkt valuation

€12.6 M

CureVac Revenue FY, 2018
CureVac Revenue growth (FY, 2017 - FY, 2018), %92%
CureVac Gross profit (FY, 2018)-9.8 M
CureVac Gross profit margin (FY, 2018), %(78%)
CureVac Net income (FY, 2018)-74.6 M
CureVac Cash, 31-Dec-201860.9 M
CureVac EV1.4 B
Get notified regarding key financial metrics and revenue changes at CureVacLearn more
Banner background

CureVac Revenue

CureVac revenue was €12.55 m in FY, 2018 which is a 92.1% year over year increase from the previous period.

Embed Graph

CureVac Funding

Summary Metrics

Founding Date

2000

CureVac total Funding

$1.1 b

CureVac latest funding size

$640 m

Time since last funding

a year ago

CureVac investors

CureVac's latest funding round in July 2020 was reported to be $640 m. In total, CureVac has raised $1.1 b. CureVac's latest valuation is reported to be $1.5 b.

CureVac Capital Raised

Embed Graph

CureVac Valuation

Embed Graph

CureVac Revenue Breakdown

Embed Graph

CureVac revenue breakdown by business segment: 37.3% from Goods Deliveries and 62.7% from Services

CureVac revenue breakdown by geographic segment: 21.7% from Germany and 78.3% from Foreign

CureVac Income Statement

Annual

EURFY, 2016FY, 2017FY, 2018

Revenue

10.8m6.5m12.6m

Revenue growth, %

(39%)92%

Cost of goods sold

11.1m17.1m22.3m

Gross profit

(373.4k)(10.6m)(9.8m)

Gross profit Margin, %

(3%)(162%)(78%)

Operating expense total

43.8m50.4m64.8m

Depreciation and amortization

7.8m4.8m3.6m

Interest expense

25.710.7k

Income tax expense

26.6k

Net Income

(44.1m)(61.0m)(74.6m)

CureVac Balance Sheet

Annual

EURFY, 2016FY, 2017FY, 2018

Cash

134.2m146.0m60.9m

Accounts Receivable

4.2m760.0k5.6m

Prepaid Expenses

778.0k446.9k5.9m

Inventories

5.4m3.7m4.1m

Current Assets

147.0m152.1m72.6m

PP&E

10.8m11.9m14.5m

Total Assets

167.5m191.3m125.2m

Accounts Payable

6.4m5.1m9.0m

Short-term debt

3.1m1.9k9.6k

Long-term debt

4.6m3.6k49.5k

Total Debt

7.7m5.5k59.1k

Total Liabilities

44.1m83.9m93.3m

Common Stock

705.5k726.6k726.6k

Retained Earnings

(148.6m)(192.7m)(329.3m)

Total Equity

123.4m107.4m31.8m

Debt to Equity Ratio

0.1 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.4 x1.8 x3.9 x

CureVac Cash Flow

Annual

EURFY, 2017FY, 2018

Depreciation and Amortization

3.1m3.6m

Accounts Payable

42.3m3.2m

Cash From Operating Activities

(14.0m)(73.7m)

Purchases of PP&E

(19.1m)(9.4m)

Cash From Investing Activities

(19.6m)(14.7m)

Cash From Financing Activities

45.0m(10.7k)

Net Change in Cash

11.4m(88.3m)

Interest Paid

10.7k

Income Taxes Paid

18.0k26.6k

CureVac Ratios

EURFY, 2016

Revenue/Employee

85.3k

Debt/Equity

0.1 x

Financial Leverage

1.4 x

CureVac Operating Metrics

Mar, 2020May, 2020

Patent Applications

500

Patents Issued

700233

Phase I Trials Products

33

Pre-Clinical Development Phase Products

27

Pre-Clinical Discovery Phase Products

76

Strategic Partners

88

Technology Partners

22